VivoSim Labs Inc
VIVS
Company Profile
Business description
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Contact
11555 Sorrento Valley road
Suite 100
San DiegoCA92121
USAT: +1 858 224-1000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
14
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,399.80 | 30.50 | 0.36% |
| CAC 40 | 7,658.93 | 37.99 | -0.49% |
| DAX 40 | 23,241.06 | 8.59 | -0.04% |
| Dow JONES (US) | 40,829.00 | 389.83 | -0.95% |
| FTSE 100 | 8,562.12 | 35.30 | -0.41% |
| HKSE | 22,691.88 | 29.17 | 0.13% |
| NASDAQ | 17,689.66 | 154.58 | -0.87% |
| Nikkei 225 | 36,779.66 | 51.03 | -0.14% |
| NZX 50 Index | 12,496.89 | 75.80 | 0.61% |
| S&P 500 | 5,606.91 | 43.47 | -0.77% |
| S&P/ASX 200 | 8,178.30 | 26.90 | 0.33% |
| SSE Composite Index | 3,342.67 | 26.55 | 0.80% |